Cidara Therapeutics Announces Janssen’s Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza
06 sept. 2023 08h00 HE
|
Cidara Therapeutics, Inc.
Decision follows promising interim efficacy and safety data from ongoing Phase 1 and 2a trials Cidara to receive a $7 million milestone payment and is eligible to receive an additional $685 million...
Cidara Therapeutics Announces Appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development
16 août 2023 08h00 HE
|
Cidara Therapeutics, Inc.
Dr. Davarpanah will lead Cidara’s oncology efforts, focusing on strategy to advance development candidates Previously served as Clinical and Translational Lead in Oncology at Genentech/Roche SAN...
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
03 août 2023 16h08 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing immunotherapeutics designed to help improve the standard of care for...
Cidara Therapeutics Provides Update on REZZAYO™ (rezafungin for injection)
31 juil. 2023 16h30 HE
|
Cidara Therapeutics, Inc.
Cidara’s U.S. Commercial Partner, Melinta Therapeutics, has Initiated Commercial Launch of REZZAYO™ EMA Regulatory Decision for Rezafungin Expected by Year End 2023 SAN DIEGO, July 31, 2023 (GLOBE...
Cidara Therapeutics Provides Update on Status of Ongoing CD388 Influenza Program
20 juil. 2023 17h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for...
Cidara Therapeutics Added to Russell Microcap® Index
26 juin 2023 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of...
Cidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B
22 juin 2023 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of...
Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit
20 juin 2023 09h55 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for...
Cidara Therapeutics to Present at Adenosine Pathway Targeted Cancer Immunotherapy Summit
13 juin 2023 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for...
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
11 mai 2023 16h37 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of...